Diagnostic algorithm based on ratio of ascites-serum tumor markers is superior to tumor markers in the differentiation of benign ascites from malignant ascites

被引:0
|
作者
Liu, Minghui [1 ]
Zhang, Nan [2 ]
Wei, Xiuqi [3 ]
Xiao, Zhuanglong [1 ]
Song, Yuhu [1 ]
Du, Li [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Div Gastroenterol, Wuhan 430022, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Endocrinol, Wuhan 430022, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Clin Lab, Wuhan 430022, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
Benign ascites; Malignant ascites; Ascitic tumor markers; Ratio of ascites-serum tumor markers; Diag nosis algorithm; CARCINOEMBRYONIC ANTIGEN; OVARIAN; PERITONITIS; MANAGEMENT; CA-19-9; FLUID; CEA;
D O I
10.1016/j.amjms.2024.06.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Differential diagnosis between benign ascites and malignant ascites remains challenging in clinical practice, the aim of our study is to determine the differential value of the ratio of ascitic-serum tumor markers between benign ascites and malignant ascites. Methods: 418 patients with new-onset ascites were retrospectively enrolled in this study. The pertinent data of patients enrolled were collected; diagnostic value of tumor markers, ascites-serum tumor marker ratio, and diagnostic algorithm based on ascitic tumor markers and ascites-serum tumor marker ratio in patients with ascites were investigated. Results: 81.25% of the patients with benign ascites had low (<1) ratio of ascites-serum tumor markers (Max EA/S CEA, A/S CA15-3, A/S CA19-9]); and 91.88% of patients with benign ascites had the ratio of ascites-serum tumor marker less than 1.5. On the other hand, 94.96% of the patients with malignant ascites had high (>= 1) ratio of ascites-serum tumor markers; and 97.29% of patients with malignant ascites had the ratio of ascites-serum tumor markers more than 0.67. Finally, diagnostic algorithm based on ascitic tumor markers and ascites-serum tumor marker ratio showed 96.37% of the sensitivity, and 94.37% of the accuracy in the diagnosis of malignant ascites, while ascitic tumor markers with a sensitivity of 78.29%, and an accuracy of 84.93%. Conclusions: Diagnostic algorithm based on ascitic tumor markers and ascites-serum tumor marker ratio exhibited an excellent performance in distinguishing benign and malignant ascites, which should be recommended in patients with new-onset ascites in clinical practice.
引用
收藏
页码:361 / 368
页数:8
相关论文
共 50 条
  • [31] Tumor Ag-specific CTL generation from tumor-associated lymphocytes (TAL) in malignant ascites of peritoneal metastases
    Kojima, Masatsugu
    Murata, Satoshi
    Shimoji, Miyuki
    Sihombing, Andreas M.
    Kitamura, Naomi
    Ueki, Tomoyuki
    Kitamura, Mina
    Takebayashi, Katsushi
    Kodama, Hirokazu
    Tokuda, Aya
    Miyake, Toru
    Mekata, Eiji
    Tani, Masaji
    CANCER SCIENCE, 2021, 112 : 393 - 393
  • [32] PLACENTAL-LIKE ALKALINE-PHOSPHATASE FROM OVARY AND ASCITES OF A PATIENT WITH A MALIGNANT OVARIAN TUMOR
    KOYAMA, I
    STENDAHL, U
    STIGBRAND, T
    CLINICA CHIMICA ACTA, 1990, 186 (02) : 295 - 299
  • [33] Significance of serum and bile tumor markers in the diagnostic approach of patients with malignant pancreatobiliary disease
    Natsios, Athanasios
    Vezakis, Antonios
    Kaparos, Georgios
    Fragulidis, Georgios
    Karakostas, Nikolaos
    Kouskouni, Evangelia
    Logothetis, Emmanouil
    Polydorou, Andreas
    JOURNAL OF BUON, 2015, 20 (04): : 1030 - 1036
  • [34] Diagnostic value of MUC1 and EpCAM mRNA as tumor markers in differentiating benign from malignant pleural effusion
    Sun, W.
    Li, J.
    Jiang, H-G.
    Ge, L-P.
    Wang, Y.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2014, 107 (12) : 1001 - 1007
  • [35] Preoperative Differentiation of Benign and Malignant Non-epithelial Ovarian Tumors: Clinical Features and Tumor Markers
    Gomes, Tiago Augusto
    Campos, Elizabeth Aparecida
    Yoshida, Adriana
    Sarian, Luis Otavio
    Lucci de Angelo Andrade, Liliana Aparecida
    Derchain, Sophie Francoise
    REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2020, 42 (09): : 555 - 561
  • [36] Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites
    My Wintzell
    Elisabet Hjerpe
    Elisabeth Åvall Lundqvist
    Maria Shoshan
    BMC Cancer, 12
  • [37] Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites
    Wintzell, My
    Hjerpe, Elisabet
    Lundqvist, Elisabeth Avall
    Shoshan, Maria
    BMC CANCER, 2012, 12
  • [38] COMBINATIONS OF MULTIPLE SERUM MARKERS ARE SUPERIOR TO INDIVIDUAL ASSAYS FOR DISCRIMINATING MALIGNANT FROM BENIGN PELVIC MASSES
    WOOLAS, RP
    CONAWAY, MR
    XU, FJ
    JACOBS, IJ
    YU, YH
    DALY, L
    DAVIES, AP
    OBRIANT, K
    BERCHUCK, A
    SOPER, JT
    CLARKEPEARSON, DL
    RODRIGUEZ, G
    ORAM, DH
    BAST, RC
    GYNECOLOGIC ONCOLOGY, 1995, 59 (01) : 111 - 116
  • [39] Activation and propagation of tumor-infiltrating lymphocytes from malignant pleural effusion and ascites with engineered cells for costimulatory enhancement
    Xu, Qiuping
    Shao, Jie
    Su, Shu
    Wei, Jia
    Chen, Fangjun
    Meng, Fanyan
    Zhao, Yang
    Du, Juan
    Zou, Zhengyun
    Qian, Xiaoping
    Liu, Baorui
    CELLULAR IMMUNOLOGY, 2018, 331 : 1 - 8
  • [40] The diagnostic value of a breast cancer diagnosis model based on serum MiRNAs and serum tumor markers
    Li, Xiaohui
    Wang, Feng
    Lin, Faquan
    Xie, Binbin
    Liu, Yi
    Xiao, Yi
    Qin, Kai
    Li, Weicheng
    Zeng, Qiyan
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2025, 23 (01)